Goodwin advised Human Immunology Biosciences (HI-Bio) on the round. Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs),...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here